一句話翻譯分享（醫學類）（9）——摘自NEJM

例句選擇NEJM PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkins Lymphoma — NEJM

To be eligible for participation in this study, patients had to be at least 18 years of age, have histologically confirmed evidence of relapsed or refractory Hodgkins lymphoma with at least one lesion measuring more than 1.5 cm (as defined by the Revised Response Criteria for Malignant Lymphomas18) (see the Supplementary Appendix, available with the full text of this article at http://NEJM.org), an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability), previous treatment with at least one chemotherapy regimen, and no autologous stem-cell transplantation within the previous 100 days.

辭彙層面：

1、Hodgkins lymphoma：霍奇金淋巴瘤（HL）是淋巴瘤的一種獨特類型，為青年人中最常見的惡性腫瘤之一。病初發生於一組淋巴結，以頸部淋巴結和鎖骨上淋巴結常見，然後擴散到其他淋巴結，晚期可侵犯血管，累及脾、肝、骨髓和消化道等。經典霍奇金淋巴瘤可分為4種組織學類型：淋巴細胞為主型、結節硬化型、混合細胞型和淋巴細胞耗竭型。近年來WHO分型中增加了一種結節性淋巴細胞為主型。我國最常見為混合細胞型。各型之間可以互相轉化。組織學亞型是決定患者臨床表現、預後和治療的主要因素。——百度百科

2、relapsed or refractory：複發或難治性

3、lesion：病灶

4、Revised Response Criteria for Malignant Lymphomas：修訂版惡性淋巴瘤治療反應標準

5、Supplementary Appendix：補充附錄

6、Eastern Cooperative Oncology Group (ECOG)：美國東部腫瘤協作組

7、performance-status score：功能狀態評分

8、chemotherapy regimen：化療方案

9、increasing disability：進一步功能障礙

句法層面：

1、斷層：

To be eligible for participation in this study,

patients

had to be at least 18 years of age,

have histologically confirmed evidence of relapsed or refractory Hodgkins lymphoma

with at least one lesion

measuring more than 1.5 cm

(as defined by the Revised Response Criteria for Malignant Lymphomas18)

(see the Supplementary Appendix, available with the full text of this article at http://NEJM.org),

an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1

(on a scale from 0 to 5,

with 0 indicating no symptoms

and higher scores indicating increasing disability),

previous treatment

with at least one chemotherapy regimen,

and no autologous stem-cell transplantation

within the previous 100 days.

主幹部分即為：To ...., patients had to ...., have .... with ... measuring.... (as defined by ...) (see ..., available with ...), an .. score of 0 or 1 (on a scale...0 indicating... and .. scores indicating), ... treatment with.. , and.. within ... .

2、To be eligible for participation in this study：入組標準（程式化翻譯，需記憶）

3、have histologically confirmed evidence of：組織學確診為....（可考慮記憶）

參考譯文為：

入組標準：患者必需至少18歲，組織學確診為複發或難治性霍奇金淋巴瘤，並至少有一個病灶大於1.5 cm (根據修訂版惡性淋巴瘤治療反應標準[Revised Response Criteria for Malignant Lymphomas]的定義）（見補充附錄，可在http://NEJM.org上刊登的本文全文中獲取），美國東部腫瘤協作組（Eastern Cooperative Oncology Group , ECOG )功能狀態評分0或1分（功能狀態評分從0~5分，0代表無癥狀，更高評分代表更進一步的功能障礙），至少接受過一種化療方案，並且近100天內未接受過自體肝細胞移植。

——————————————————————————————————如有其它見解，煩請留言探討